Spinal 5-HT7 receptor activation induces long-lasting phrenic motor facilitation.
Acute intermittent hypoxia elicits a form of serotonin-dependent respiratory plasticity known as phrenic long term facilitation (pLTF). Episodic spinal serotonin-2 (5-HT2) receptor activation on or near phrenic motor neurons is necessary for pLTF. A hallmark of pLTF is the requirement for serotonin-dependent synthesis of brain-derived neurotrophic factor (BDNF), and activation of its high affinity receptor, TrkB. Activation of spinal Gs protein-coupled adenosine 2A receptors (GsPCRs) elicits a unique form of long-lasting phrenic motor facilitation (PMF), but via unique mechanisms (BDNF independent TrkB trans-activation).We hypothesized that other GsPCRs elicit PMF, specifically serotonin-7 (5-HT7) receptors, which are expressed in phrenic motor neurons. Cervical spinal (C4) injections of a selective 5-HT7 receptor agonist, AS-19 (10 μM, 5 μl; 3 × 5 min), in anaesthetized, vagotomized and ventilated male Sprague-Dawley rats elicited long-lasting PMF (>120 min), an effect prevented by pretreatment with a 5-HT7 receptor antagonist (SB 269970; 5mM, 7 μl).GsPCR activation 'trans-activates'TrkB by increasing synthesis of an immature TrkB isoform. Spinal injection of a TrkB inhibitor (k252a) and siRNAs that prevent TrkB (but not BDNF) mRNA translation both blocked 5-HT7 agonist-induced PMF, confirming a requirement for TrkB synthesis and activity. k252a affected late PMF (≥ 90 min) only. Spinal inhibition of the PI3K/AKT pathway blocked 5-HT7 agonist-induced PMF, whereas MEK/ERK inhibition delayed, but did not block, PMF. An understanding of signalling mechanisms giving rise to PMF may guide development of novel therapeutic strategies to treat ventilatory control disorders associated with respiratory insufficiency, such as spinal injury and motor neuron disease.
Department of Comparative Biosciences, University of Wisconsin, 2015 Linden Drive, Madison, WI, 53706, USA.
M S
MS
Hoffman
G S
GS
Mitchell
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D009046:Motor Neurons / Q000187:drug effects / Q000378:metabolism*; D010791:Phrenic Nerve / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020813:Receptor, trkB / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
D019208:Brain-Derived Neurotrophic Factor; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C104425:serotonin 7 receptor; D020813:Receptor, trkB
J Neurosci. 2006 Sep 6;26(36):9250-63
16957081
J Neuropathol Exp Neurol. 2007 May;66(5):363-71
17483693
Curr Opin Neurobiol. 2000 Oct;10(5):587-92
11084321
J Neurosci. 2002 Jul 15;22(14):6239-46
12122082
J Biol Chem. 2002 Mar 15;277(11):9096-102
11784714
J Neurosci. 2001 Apr 1;21(7):2442-50
11264318
J Appl Physiol (1985). 2001 May;90(5):2001-6; discussion 2000
11299296
Learn Mem. 1999 May-Jun;6(3):243-56
10492006
J Neurosci. 2004 Jul 28;24(30):6650-8
15282267
Pediatrics. 2004 Sep;114(3):805-16
15342857
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19115-20
16357196
J Neurosci. 2008 Feb 27;28(9):2033-42
18305238
Exp Neurol. 2009 May;217(1):116-23
19416672
J Physiol. 1993 Feb;461:213-33
8350262
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17210-5
17940030
J Physiol. 2010 Jan 1;588(Pt 1):255-66
19900961
J Appl Physiol (1985). 2003 Jan;94(1):358-74
12486024
Brain Res. 2003 Feb 21;964(1):56-66
12573513
Chest. 1976 Jul;70(1 Suppl):154-7
939134
Am J Physiol Regul Integr Comp Physiol. 2004 Feb;286(2):R334-41
14551171
Cytokine Growth Factor Rev. 2002 Feb;13(1):11-7
11750876
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3555-60
11248116
Neurosci Res. 2003 Jun;46(2):127-34
12767475
Eur J Neurosci. 2006 Jun;23(12):3375-84
16820027
Brain Res Mol Brain Res. 1996 Mar;36(2):280-6
8965648
Annu Rev Neurosci. 2003;26:239-66
12598679
Exp Physiol. 2007 Jan;92(1):27-37
17099064
J Neurosci. 2002 Jun 15;22(12):4860-8
12077183
Ann N Y Acad Sci. 1999;890:79-92
10668415
Neuroscience. 2001;102(2):361-7
11166122
Cell. 2004 Feb 6;116(3):467-79
15016380
J Physiol. 2009 Feb 15;587(Pt 4):713-9
19218620
J Comp Neurol. 1981 Sep 20;201(3):441-56
7276259
J Neurochem. 2003 Dec;87(5):1076-85
14622088
Curr Opin Neurobiol. 2005 Oct;15(5):607-13
16150586
Nat Neurosci. 2004 Jan;7(1):48-55
14699417
Neurosci Lett. 2004 Jun 10;363(2):108-11
15172095
Oncogene. 1992 Feb;7(2):371-81
1312698
J Appl Physiol (1985). 2001 Jun;90(6):2466-75
11356815
J Neurophysiol. 2009 Jul;102(1):337-48
19458153
Respir Physiol Neurobiol. 2008 Dec 10;164(1-2):242-51
18634908
J Neurosci. 2005 Mar 16;25(11):2925-32
15772352
Nat Rev Neurosci. 2003 Apr;4(4):299-309
12671646
Oncogene. 2000 Nov 20;19(49):5548-57
11114734
Ann N Y Acad Sci. 2001 Jun;939:74-84
11462806
Neuroscience. 2008 Mar 3;152(1):189-97
18207649
Eur J Neurosci. 2006 Jul;24(2):535-46
16836640
Behav Brain Res. 2005 Aug 30;163(1):136-40
15936093
J Comp Neurol. 2005 Sep 26;490(3):256-69
16082681
J Neurobiol. 1999 May;39(2):323-36
10235685
Psychol Bull. 1984 Nov;96(3):518-59
6096908